Testing a new drug for ulcerative colitis after other treatments failed
Part of Digestive system clinical trials.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with ulcerative colitis for at least 3 months (confirmed by a colonoscopy and biopsy).
- You have tried a biologic or targeted therapy (like a TNF blocker or JAK inhibitor) and it didn't work well, stopped working, or caused side effects.
- You do not have Crohn's disease, another type of colitis, or certain other bowel conditions.
- You have not had surgery for colitis (like J-pouch, ileostomy, or colostomy) unless approved by the study doctor.
- You are willing to use effective birth control if you are of childbearing age or a man with a partner who could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.